Loading…
Reported covered position: Education and Workforce Committee 1999-2001
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Protect Medical Innovation Act of 2015
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Protect Medical Innovation Act of 2015
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2015 · third_quarter · 3A
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Source: Senate LDA
| OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES |
| 5 |
| 2014–2015 |
| BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS | 4 | 2014–2015 |
| ORACLE | 4 | 2015 |
| PROFESSIONAL COMPOUNDING CENTERS OF AMERICA | 4 | 2014–2015 |
| WELLNESS PHARMACY | 2 | 2014 |
| TONKON TORP ON BEHALF OF DEROYAL MEDICAL PRODUCTS | 1 | 2015 |
Protect Medical Innovation Act of 2015
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Protect Medical Innovation Act of 2015
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Protect Medical Innovation Act of 2015
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Protecting Affordable Coverage for Employees Act
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability, health information technology, transparency, employer regulations, and taxes and fees; Issues related to HR 1624 - to revise the definition of small employer.
Protecting Affordable Coverage for Employees Act
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
issues related to Public Law 111-148, 111-152, implementation of Affordable Care Act, benefits, affordability, health information technology, transparency, employer regulations, taxes and fees; issues related to HR 1624
Protecting Affordable Coverage for Employees Act
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability, health information technology, transparency, employer regulations, and taxes and fees; Issues related to HR 1624 - to revise the definition of small employer.
Protecting Affordable Coverage for Employees Act
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability, health information technology, transparency, employer regulations, and taxes and fees; Issues related to HR 1624 - to revise the definition of small employer.
Protecting Affordable Coverage for Employees Act
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
issues related to Public Law 111-148, 111-152, implementation of Affordable Care Act, benefits, affordability, health information technology, transparency, employer regulations, taxes and fees; issues related to HR 1624
Protecting Affordable Coverage for Employees Act
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
issues related to Public Law 111-148, 111-152, implementation of Affordable Care Act, benefits, affordability, health information technology, transparency, employer regulations, taxes and fees; issues related to HR 1624
Protecting Affordable Coverage for Employees Act
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability, health information technology, transparency, employer regulations, and taxes and fees; Issues related to HR 1624 - to revise the definition of small employer.
Protecting Affordable Coverage for Employees Act
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
issues related to Public Law 111-148, 111-152, implementation of Affordable Care Act, benefits, affordability, health information technology, transparency, employer regulations, taxes and fees; issues related to HR 1624
Medicare Access and CHIP Reauthorization Act of 2015
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; Issues related to HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
Medicare Access and CHIP Reauthorization Act of 2015
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; Issues related to HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
Medicare Access and CHIP Reauthorization Act of 2015
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; Issues related to HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
Medicare Access and CHIP Reauthorization Act of 2015
Client: CVS PREVIOUSLY AETNA · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; Issues related to HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to the availability of epinephrine. General Health issues, including but not limited to, coverage and reimbursement; drug
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
File Once FAFSA Act of 2016
Client: BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
issues relating to Medicare and Medicaid; Medicaid Generic Drug Pricing Fairness Act H.R.5784, S.2948
Oversight of implantation of the America Invents Act Issues relating to patent settlements H.R.9-The Innovation Act
Oversight of implantation of the America Invents Act Issues relating to patent settlements H.R.9-The Innovation Act
Oversight of implantation of the America Invents Act Issues relating to patent settlements H.R.9-The Innovation Act
Oversight of implantation of the America Invents Act Issues relating to patent settlements H.R.9-The Innovation Act
Oversight of implantation of the America Invents Act Issues relating to patent settlements H.R.9-The Innovation Act
Patient Access to Higher Quality Health Care Act of 2015
Client: MCBRIDE ORTHOPEDIC HOSPITAL · Firm: CAPITOL HILL CONSULTING GROUP
General issues relating to physicians, ownership at hospitals; H.R.976 Patient Access Higher Quality Health Care Act of 2015
Patient Access to Higher Quality Health Care Act of 2015
Client: MCBRIDE ORTHOPEDIC HOSPITAL · Firm: CAPITOL HILL CONSULTING GROUP
General issues relating to physicians, ownership at hospitals; H.R.976 Patient Access Higher Quality Health Care Act of 2015
Patient Access to Higher Quality Health Care Act of 2015
Client: MCBRIDE ORTHOPEDIC HOSPITAL · Firm: CAPITOL HILL CONSULTING GROUP
General issues relating to physicians, ownership at hospitals; H.R.976 Patient Access Higher Quality Health Care Act of 2015
Patient Access to Higher Quality Health Care Act of 2015
Client: MCBRIDE ORTHOPEDIC HOSPITAL · Firm: CAPITOL HILL CONSULTING GROUP
General issues relating to physicians, ownership at hospitals; H.R.976 Patient Access Higher Quality Health Care Act of 2015
Supporting quality of life for prostate cancer patients.
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Supporting quality of life for prostate cancer patients.
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
Supporting quality of life for prostate cancer patients.
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Supporting quality of life for prostate cancer patients.
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Supporting quality of life for prostate cancer patients.
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Supporting quality of life for prostate cancer patients.
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
Supporting quality of life for prostate cancer patients.
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
Supporting quality of life for prostate cancer patients.
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Supporting quality of life for prostate cancer patients.
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
Saving Access to Compounded Medications for Special Needs Patients Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to PL 113-54, The Drug Quality and Security Act Issues related to agriculture appropriations and defense appropriations. Issues related to S. 1406 - saving access to compound medications for special needs patients act.
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Ensuring Safe Access to Prescription Medication Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Ensuring Safe Access to Prescription Medication Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Ensuring Safe Access to Prescription Medication Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to tamper resistant formulation of pharmaceutical drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Ensuring Safe Access to Prescription Medication Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Ensuring Safe Access to Prescription Medication Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Issues related to tamper resistant formulation of pharmaceutical drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Medicaid Generic Drug Price Fairness Act
Client: BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
issues relating to Medicare and Medicaid; Medicaid Generic Drug Pricing Fairness Act H.R.5784, S.2948
Cutting Costly Codes Act of 2013
Client: MCBRIDE ORTHOPEDIC HOSPITAL · Firm: CAPITOL HILL CONSULTING GROUP
General issues relating to physicians to hospitals HR 2027- Expanding Patients' Access to Quality Care Act of 2013 HR 1701 and S 972- Cutting Costly Codes Act of 2013
Cutting Costly Codes Act of 2013
Client: MCBRIDE ORTHOPEDIC HOSPITAL · Firm: CAPITOL HILL CONSULTING GROUP
General issues relating to physicians to hospitals; Expanding Patients' Access to Quality Care Act of 2013 H.R.2027; Cutting Costly Codes Act of 2013 H.R.1701, S.972
Expanding Patients' Access to Quality Care Act of 2013
Client: MCBRIDE ORTHOPEDIC HOSPITAL · Firm: CAPITOL HILL CONSULTING GROUP
General issues relating to physicians to hospitals HR 2027- Expanding Patients' Access to Quality Care Act of 2013 HR 1701 and S 972- Cutting Costly Codes Act of 2013
Expanding Patients' Access to Quality Care Act of 2013
Client: MCBRIDE ORTHOPEDIC HOSPITAL · Firm: CAPITOL HILL CONSULTING GROUP
General issues relating to physicians to hospitals; Expanding Patients' Access to Quality Care Act of 2013 H.R.2027; Cutting Costly Codes Act of 2013 H.R.1701, S.972
Compounding Clarity Act of 2013
Client: WELLNESS PHARMACY · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act S.959 The Compound Clarity Act H.R.3089 The Drug Quality and Security Act H.R.3204 Issues related to implementation of the Compounding Quality Act
Compounding Clarity Act of 2013
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act
Compounding Clarity Act of 2013
Client: WELLNESS PHARMACY · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act
Compounding Clarity Act of 2013
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act S.959 The Compound Clarity Act H.R.3089 The Drug Quality and Security Act H.R.3204 2015 National Defense Authorization Act Issues related to implementation of the Compounding Quality Act
Drug Quality and Security Act
Client: WELLNESS PHARMACY · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act S.959 The Compound Clarity Act H.R.3089 The Drug Quality and Security Act H.R.3204 Issues related to implementation of the Compounding Quality Act
Drug Quality and Security Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act
Drug Quality and Security Act
Client: WELLNESS PHARMACY · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act
Drug Quality and Security Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act S.959 The Compound Clarity Act H.R.3089 The Drug Quality and Security Act H.R.3204 2015 National Defense Authorization Act Issues related to implementation of the Compounding Quality Act
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Medical Device Tax Repeal; Stop Corporate Inversions Act S. 2360, H.R. 4679; issues relating to incentive for life sciences research' Protect Medical Innovation Act of 2013 S.232, H.R.523
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Medical Device Tax Repeal; Stop Corporate Inversions Act (S.2360) (H.R.4679); issues relating to incentives for life sciences research; Protect Medical Innovation Act of 2013 (S.232) (H.R.523)
Stop Tampering of Prescription Pills Act of 2013
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimilars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013; Able Act H.R. 647; Medicaid Generic Drug Price Fairness Act H.R.5748, S.2984
Stop Tampering of Prescription Pills Act of 2013
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Stop Tampering of Prescription Pills Act of 2013
Client: PURDUE PHARMA LLP · Firm: CAPITOL HILL CONSULTING GROUP
Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R.486)
Stop Tampering of Prescription Pills Act of 2013
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013
Protect Medical Innovation Act of 2013
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Medical Device Tax Repeal; Stop Corporate Inversions Act S. 2360, H.R. 4679; issues relating to incentive for life sciences research' Protect Medical Innovation Act of 2013 S.232, H.R.523
Protect Medical Innovation Act of 2013
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Medical Device Tax Repeal; Stop Corporate Inversions Act (S.2360) (H.R.4679); issues relating to incentives for life sciences research; Protect Medical Innovation Act of 2013 (S.232) (H.R.523)
Medicaid Generic Drug Price Fairness Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimilars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013; Able Act H.R. 647; Medicaid Generic Drug Price Fairness Act H.R.5748, S.2984
GI Bill STEM Extension Act of 2014
Client: BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
issues relating to Medicare and Medicaid; Medicaid Generic Drug Pricing Fairness Act H.R.5784, S.2948
Medical Device Access and Innovation Protection Act
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Medical Device Tax Repeal; Stop Corporate Inversions Act (S.2360) (H.R.4679); issues relating to incentives for life sciences research; Protect Medical Innovation Act of 2013 (S.232) (H.R.523)
Medical Device Access and Innovation Protection Act
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Medical Device Tax Repeal; Stop Corporate Inversions Act S. 2360, H.R. 4679; issues relating to incentive for life sciences research' Protect Medical Innovation Act of 2013 S.232, H.R.523
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Medical Device Tax Repeal; Stop Corporate Inversions Act S. 2360, H.R. 4679; issues relating to incentive for life sciences research' Protect Medical Innovation Act of 2013 S.232, H.R.523
Stop Corporate Inversions Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Medical Device Tax Repeal; Stop Corporate Inversions Act (S.2360) (H.R.4679); issues relating to incentives for life sciences research; Protect Medical Innovation Act of 2013 (S.232) (H.R.523)
Ensuring Safe Access to Prescription Medication Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Ensuring Safe Access to Prescription Medication Act of 2014 (S.2825)
Ensuring Safe Access to Prescription Medication Act of 2014
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
Ensuring Safe Access to Prescription Medication Act of 2014 S.2825
Medicaid Generic Drug Price Fairness Act
Client: BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
issues relating to Medicare and Medicaid; Medicaid Generic Drug Pricing Fairness Act H.R.5784, S.2948
A bill to modify the definition of cotton futures contracts in the United States Cotton Futures Act.
Client: ENDO PHARMACEUTICALS · Firm: CAPITOL HILL CONSULTING GROUP
general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimilars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013; Able Act H.R. 647; Medicaid Generic Drug Price Fairness Act H.R.5748, S.2984
Pharmaceutical Quality, Security, and Accountability Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act S.959 The Compound Clarity Act H.R.3089 The Drug Quality and Security Act H.R.3204 2015 National Defense Authorization Act Issues related to implementation of the Compounding Quality Act
Pharmaceutical Quality, Security, and Accountability Act
Client: WELLNESS PHARMACY · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act
Pharmaceutical Quality, Security, and Accountability Act
Client: WELLNESS PHARMACY · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act S.959 The Compound Clarity Act H.R.3089 The Drug Quality and Security Act H.R.3204 Issues related to implementation of the Compounding Quality Act
Pharmaceutical Quality, Security, and Accountability Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: CAPITOL HILL CONSULTING GROUP
Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act
Cutting Costly Codes Act of 2013
Client: MCBRIDE ORTHOPEDIC HOSPITAL · Firm: CAPITOL HILL CONSULTING GROUP
General issues relating to physicians to hospitals; Expanding Patients' Access to Quality Care Act of 2013 H.R.2027; Cutting Costly Codes Act of 2013 H.R.1701, S.972
Cutting Costly Codes Act of 2013
Client: MCBRIDE ORTHOPEDIC HOSPITAL · Firm: CAPITOL HILL CONSULTING GROUP
General issues relating to physicians to hospitals HR 2027- Expanding Patients' Access to Quality Care Act of 2013 HR 1701 and S 972- Cutting Costly Codes Act of 2013
Issues related to Labor-HHS funding
Controlled Drug Substances Act (21 USC 13)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2015 · third_quarter · 3A
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Oversight of implantation of the America Invents Act Issues relating to patent settlements H.R.9-The Innovation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2015 · fourth_quarter · Q4
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement
Issues related to Labor-HHS funding
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Controlled Drug Substances Act (21 USC 13)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2015 · fourth_quarter · Q4
Federal Student Loans/Aid
General health care issues pertaining to OSU-CHS; NIH
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Graduate Medical Education funding; Issues related to physician shortage.
Government funding of medical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCBRIDE ORTHOPEDIC HOSPITAL via CAPITOL HILL CONSULTING GROUP
2015 · fourth_quarter · Q4
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
General issues relating to physicians, ownership at hospitals; H.R.976 Patient Access Higher Quality Health Care Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CVS PREVIOUSLY AETNA via CAPITOL HILL CONSULTING GROUP
2015 · fourth_quarter · Q4
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; Issues related to the Affordable Care Act's implementation, including Medical Loss Ratio, taxes, Exchanges, Essential health Benefits, premium affordability, health information technology, transparency, and employer regulations;
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; Corporate tax reform; Cadillac Tax and Health Insurance Tax Repeal and Delay.
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; Issues related to HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
DEROYAL INDUSTRIES, INC. via CAPITOL HILL CONSULTING GROUP
2015 · fourth_quarter · Q4
Issues related to Medicare payment policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORACLE via CAPITOL HILL CONSULTING GROUP
2015 · fourth_quarter · Q4
ACA and state exchanges oversight and ongoing operational issues.
General higher education issues; Higher Education Act Reauthorization
Corporate and International Tax Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2015 · fourth_quarter · Q4
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act.
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2015 · fourth_quarter · Q4
H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to the availability of epinephrine. General Health issues, including but not limited to, coverage and reimbursement; drug
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2015 · third_quarter · Q3
Issues related to Labor-HHS funding
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Controlled Drug Substances Act (21 USC 13)
ORACLE via CAPITOL HILL CONSULTING GROUP
2015 · third_quarter · Q3
Corporate and International Tax Reform
General higher education issues; Higher Education Act Reauthorization
ACA and state exchanges; King v. Burwell
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2015 · third_quarter · Q3
Government funding of medical research.
Federal Student Loans/Aid
General health care issues pertaining to OSU-CHS; NIH
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2015 · third_quarter · Q3
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act.
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCBRIDE ORTHOPEDIC HOSPITAL via CAPITOL HILL CONSULTING GROUP
2015 · third_quarter · Q3
General issues relating to physicians, ownership at hospitals; H.R.976 Patient Access Higher Quality Health Care Act of 2015
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2015 · third_quarter · Q3
Oversight of implantation of the America Invents Act Issues relating to patent settlements H.R.9-The Innovation Act
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
DEROYAL INDUSTRIES, INC. via CAPITOL HILL CONSULTING GROUP
2015 · third_quarter · Q3
Issues related to Medicare payment policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CVS PREVIOUSLY AETNA via CAPITOL HILL CONSULTING GROUP
2015 · third_quarter · Q3
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; Issues related to HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; Issues related to the Affordable Care Act's implementation, including Medical Loss Ratio, taxes, Exchanges, Essential health Benefits, premium affordability, health information technology, transparency, and employer regulations;
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2015 · second_quarter · Q2
Controlled Drug Substances Act (21 USC 13)
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement
Issues related to Labor-HHS funding
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via CAPITOL HILL CONSULTING GROUP
2015 · second_quarter · Q2
Issues related to PL 113-54, The Drug Quality and Security Act Issues related to agriculture appropriations and defense appropriations. Issues related to S. 1406 - saving access to compound medications for special needs patients act.
Issues related to DOD health/pharmacy programs
Filing targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ORACLE via CAPITOL HILL CONSULTING GROUP
2015 · second_quarter · Q2
Corporate and International Tax Reform
ACA and state exchanges; King v. Burwell
General higher education issues; Higher Education Act Reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2015 · second_quarter · Q2
General health care issues pertaining to OSU-CHS; NIH
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Graduate Medical Education funding' SGR
Federal Student Loans/Aid
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2015 · second_quarter · Q2
Issues related to Biosimilar Approvals
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCBRIDE ORTHOPEDIC HOSPITAL via CAPITOL HILL CONSULTING GROUP
2015 · second_quarter · Q2
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
General issues relating to physicians, ownership at hospitals; H.R.976 Patient Access Higher Quality Health Care Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2015 · second_quarter · Q2
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Oversight of implantation of the America Invents Act Issues relating to patent settlements H.R.9-The Innovation Act
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
DEROYAL INDUSTRIES, INC. via CAPITOL HILL CONSULTING GROUP
2015 · second_quarter · Q2
Issues related to Medicare payment policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CVS PREVIOUSLY AETNA via CAPITOL HILL CONSULTING GROUP
2015 · second_quarter · Q2
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; Corporate tax reform;
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; Issues related to HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
TONKON TORP ON BEHALF OF DEROYAL MEDICAL PRODUCTS via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · Q1
issues related to tax and health
issues related but not limited to health and tax
Medicare payment issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CVS PREVIOUSLY AETNA via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · Q1
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; Corporate tax reform;
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; Issues related to HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
DEROYAL INDUSTRIES, INC. via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · 1A
issues related to Medicare payment policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEROYAL INDUSTRIES, INC. via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · Q1
issues related to Medicare payment policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · 1T
budget and appropriations issues related to the company
issues relating to health
issues relating to Medicare and Medicaid; Medicaid Generic Drug Pricing Fairness Act H.R.5784, S.2948
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · Q1
issues related to DOD health/pharmacy programs
issues related to PL 113-54, The Drug Quality and Security Act issues related to agriculture appropriations
Filing targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MCBRIDE ORTHOPEDIC HOSPITAL via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · Q1
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
General issues relating to physicians, ownership at hospitals; H.R.976 Patient Access Higher Quality Health Care Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · Q1
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106; General Health issues, including but not limited to, coverage and reimbursement; drug
Oversight of implantation of the America Invents Act Issues relating to patent settlements H.R.9-The Innovation Act
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · Q1
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement
issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
issues related to Labor-HHS funding
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · Q1
Issues related to Biosimilar Approvals
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORACLE via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · Q1
ACA and state exchanges; King v. Burwell
general higher education issues; Higher Education Act Reauthorization
Corporate and International Tax Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · Q1
general Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Graduate Medical Education funding' SGR
general health care issues pertaining to OSU-CHS; NIH
Federal Student Loans/Aid
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CVS PREVIOUSLY AETNA via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · RR
issues related to Public Law 111-148, 111-152, implementation of Affordable Care Act, benefits, affordability, health information technology, transparency, employer regulations, taxes and fees; issues related to HR 1624
issues related to Public Law 111-148, 111-152, implementation of Affordable Care Act, benefits, affordability, health information technology, transparency, employer regulations, taxes and fees; issues related to HR 1624
issues related to Public Law 111-148, 111-152, implementation of Affordable Care Act, benefits, affordability, health information technology, transparency, employer regulations, taxes and fees; issues related to HR 1624
DEROYAL INDUSTRIES, INC. via CAPITOL HILL CONSULTING GROUP
2015 · first_quarter · RR
Issues related to Medicare payment policies
BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2014 · fourth_quarter · Q4
tax issues
issues relating to Medicare and Medicaid; Medicaid Generic Drug Pricing Fairness Act H.R.5784, S.2948
issues relating to insurance coverage
WELLNESS PHARMACY via CAPITOL HILL CONSULTING GROUP
2014 · fourth_quarter · Q4
Pharmaceutical Compounding and Accountability Act S.959 The Compound Clarity Act H.R.3089 The Drug Quality and Security Act H.R.3204 Issues related to implementation of the Compounding Quality Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via CAPITOL HILL CONSULTING GROUP
2014 · fourth_quarter · Q4
Pharmaceutical Compounding and Accountability Act S.959 The Compound Clarity Act H.R.3089 The Drug Quality and Security Act H.R.3204 2015 National Defense Authorization Act Issues related to implementation of the Compounding Quality Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MCBRIDE ORTHOPEDIC HOSPITAL via CAPITOL HILL CONSULTING GROUP
2014 · fourth_quarter · Q4
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
General issues relating to physicians to hospitals; Expanding Patients' Access to Quality Care Act of 2013 H.R.2027; Cutting Costly Codes Act of 2013 H.R.1701, S.972
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2014 · fourth_quarter · Q4
general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimilars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013; Able Act H.R. 647; Medicaid Generic Drug Price Fairness Act H.R.5748, S.2984
Ensuring Safe Access to Prescription Medication Act of 2014 S.2825
Medical Device Tax Repeal; Stop Corporate Inversions Act S. 2360, H.R. 4679; issues relating to incentive for life sciences research' Protect Medical Innovation Act of 2013 S.232, H.R.523
OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES via CAPITOL HILL CONSULTING GROUP
2014 · fourth_quarter · Q4
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Graduate Medical Education funding; SGR
General Healthcare issues pertaining to OSU-CHS; NIH
Federal Student Loans/Aid
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2014 · fourth_quarter · Q4
Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R.486)
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
general health issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; issues relating to prescription drug abuse; Canada compliance issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS CORPORATION via CAPITOL HILL CONSULTING GROUP
2014 · fourth_quarter · Q4
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2014 · third_quarter · 3A
budget and appropriations issues
issues relating to safety, drug labeling
issues relating to health
PURDUE PHARMA LLP via CAPITOL HILL CONSULTING GROUP
2014 · third_quarter · Q3
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement
General health issues related to pharmaceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC 9); drug safety; issues relating to prescription drug abuse; Canada compliance issues
Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WELLNESS PHARMACY via CAPITOL HILL CONSULTING GROUP
2014 · third_quarter · Q3
Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCBRIDE ORTHOPEDIC HOSPITAL via CAPITOL HILL CONSULTING GROUP
2014 · third_quarter · Q3
General Medicare and Medicaid issues, including but not limited to, coverage and reimbursement
General issues relating to physicians to hospitals HR 2027- Expanding Patients' Access to Quality Care Act of 2013 HR 1701 and S 972- Cutting Costly Codes Act of 2013
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via CAPITOL HILL CONSULTING GROUP
2014 · third_quarter · Q3
Pharmaceutical Compounding and Accountability Act (S.959) The Compound Clarity Act (H.R.3089) The Drug Quality and Security Act (H.R.3204) Issues related to implementation of the Compounding Quality Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ENDO PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2014 · third_quarter · Q3
general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013
general Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Ensuring Safe Access to Prescription Medication Act of 2014 (S.2825)
BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS via CAPITOL HILL CONSULTING GROUP
2014 · third_quarter · RR
Issues relating to health, pharma, pharmacy, tax, budget, Medicare, FDA, and health insurance
Issues relating to health, pharma, pharmacy, tax, budget, Medicare, FDA, and health insurance
Issues relating to health, pharma, pharmacy, tax, budget, Medicare, FDA, and health insurance
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability, health information technology, transparency, employer regulations, and taxes and fees; Issues related to HR 1624 - to revise the definition of small employer.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Oversight of implantation of the America Invents Act Issues relating to patent settlements H.R.9-The Innovation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Medicare and Medicaid issues including, but not limited to, coverage reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Graduate Medical Education funding' SGR
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability, health information technology, transparency, employer regulations, and taxes and fees; Issues related to HR 1624 - to revise the definition of small employer.
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; Corporate tax reform;
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act; HR.471- Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tamper resistant formulation of pharmaceutical drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability, health information technology, transparency, employer regulations, and taxes and fees; Issues related to HR 1624 - to revise the definition of small employer.
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; Issues related to the Affordable Care Act's implementation, including Medical Loss Ratio, taxes, Exchanges, Essential health Benefits, premium affordability, health information technology, transparency, and employer regulations;
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; Issues related to the Affordable Care Act's implementation, including Medical Loss Ratio, taxes, Exchanges, Essential health Benefits, premium affordability, health information technology, transparency, and employer regulations;
Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability, health information technology, transparency, employer regulations, and taxes and fees; Issues related to HR 1624 - to revise the definition of small employer.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
issues related to, but not limited to, pharmacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tamper resistant formulation of pharmaceutical drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Issues relating to incentives for life sciences research H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Controlled Drug Substances Act (21 USC 13)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
issues related to Public Law 111-148, 111-152, implementation of Affordable Care Act, benefits, affordability, health information technology, transparency, employer regulations, taxes and fees; issues related to HR 1624
issues relating to health
budget and appropriations issues related to the company
issues related to, but not limited to, pharmacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
issues relating to insurance coverage
issues relating to Medicare and Medicaid
issues relating to, but not limited to pharmacy
tax issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medical Device Tax Repeal; Stop Corporate Inversions Act (S.2360) (H.R.4679); issues relating to incentives for life sciences research; Protect Medical Innovation Act of 2013 (S.232) (H.R.523)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to health, pharma, pharmacy, tax, budget, Medicare, FDA, and health insurance
Issues relating to health, pharma, pharmacy, tax, budget, Medicare, FDA, and health insurance
Issues relating to health, pharma, pharmacy, tax, budget, Medicare, FDA, and health insurance
Issues relating to health, pharma, pharmacy, tax, budget, Medicare, FDA, and health insurance